Compare Nuwellis Inc (NUWE) vs OneSpan Inc (OSPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs OneSpan Inc — how do they compare? Nuwellis Inc trades at $2.84 (market cap $1.09M), while OneSpan Inc trades at $15.37 (market cap $575.37M). The key difference: OneSpan Inc is far larger — about 527.9× Nuwellis Inc's market cap, and OneSpan Inc pays a 3.35% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| NUWE | OSPN | |
|---|---|---|
Market Cap | $1.09M | $575.37M |
Sector | Technology | Technology |
52-Week High | $527.46 | $16.32 |
52-Week Low | $2.80 | $10.15 |
Enterprise Value | -$722.58K | $533.57M |
Dividend Yield | — | 3.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $3.00, up 5.26% today, following a 35:1 reverse stock split effective June 26, 2026. The company shows a low P/E of 0.06 and P/S of 0.01, but fundamentals are weak with a -217.22% net income margin and negative ROE. Recent news highlights patent awards and pediatric market expansion, yet cash flow remains negative. Analyst coverage is limited with a split buy/hold consensus.
Outlook is speculative; growth depends on successful commercialization of Aquadex therapy and cost management. Key risks include persistent losses, high cash burn, and competitive pressures. Investors should weigh low valuation against execution risks in the medical technology sector.
OneSpan (OSPN) trades at $15.51, showing modest daily gains of 0.26% with strong technical momentum indicated by bullish moving averages. The company demonstrates robust profitability with a 28.47% net income margin and consistent earnings beats in recent quarters. Recent corporate developments include a $0.13 dividend payment and upcoming Q2 2026 earnings announcement on August 4, 2026.
The stock presents attractive valuation metrics with a P/E of 8.55 and strong analyst support (66.7% buy ratings), though current price exceeds the $13.50 consensus target. Key risks include negative cash flow trends and competitive pressures in the cybersecurity sector. Earnings growth remains the primary catalyst for further upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →
